Oncode is the independent institute dedicated to outsmarting cancer and impacting lives.
Carl Figdor and Michiel Vermeulen participate in the Oncode Institute for Radboudumc and Radboud University, respectively.
Research programmeDespite enormous progress in our understanding of cancer, the chance of long-term survival remains small for many patients, particularly those with metastatic disease. Oncode will address this unmet clinical need through an innovative basic research programme. True innovation in the treatment of cancer relies on new insights into the basic mechanisms of oncogenesis, which in turn depend heavily on technological innovation. Oncode research will be guided by a number of key questions that need to be resolved to extend life expectancy and improve quality of life for cancer patients.
Principal scientific questionsThe key issues in cancer research today are summed up in our principal scientific questions:
- Can we define new and better targets for therapy on the basis of detailed analyses of tumours, tumour-derived cell lines and organoids, and xenografts?
- What is the basis for tumour heterogeneity, and how can we harness this knowledge to refine cancer therapy?
- What role does the cell of origin play in a tumour’s characteristics and responsiveness to therapy?
- How do cancer cells avoid host immune attack, and how can we stop them from doing so?
- How do non-mutated background genes influence tumour formation and response to therapy?
- Can we develop novel models to predict therapy response?
- How can we prevent metastatic disease?
Scientific themesOn the basis of these questions, Oncode’s founding scientists have identified six scientific themes that constitute the basis of the integrated research strategy:
- Development of novel technologies
- Understanding the critical drivers of tumour growth and the causes of resistance
- Analysis of network perturbations in tumours and tumour-host interactions
- Causes and consequences of genetic instability
- Identification of critical drug combinations and biomarkers for personalized cancer treatments
- Mobilizing immune defence
Read more on the Oncode website.
Related news items
Cognitive behavioral therapy effective in MD1 New treatment option for complex disease21 September 2018
Treatment with cognitive behavioral therapy helps patients with myotonic dystrophy type 1 in improving their physical abilities and social participation. This is the result of a survey of more than 250 patients in four European countries.read more
Rebecca Halbach receives poster prize at EMBO conference20 September 2018
Rebecca Halbach, theme Infectious diseases and global health, has received a poster prize at the EMBO Workshop ‘piRNAs and PIWI proteins’, held in Montpellier, France.read more
Netherlands X-omics Initiative: Consortium kick off meeting20 September 2018
The Netherlands X-omics Initiative had their consortium kick-off meeting. Consortium members from the Dutch partners involved gathered to get to know each other and to determine the next steps to start up the project.read more
A personal touch of Carine van der Vleuten20 September 2018
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t! This week: Carine van der Vleuten.read more
Successful teamwork between Neurology and Human Genetics leads to identification of two new ataxia genes19 September 2018
Thanks to close cooperation between Bart van de Warrenburg (Neurology) and Erik-Jan Kamsteeg (Humans Genetics) two new genes involved in movement disorders were identified. The genes are relevant for autosomal recessive cerebellar ataxia.read more